



Annual Shareholders Meeting

11 September 2025



NATIONAL MEDICAL PRODUCTS ADMINISTRATION
国家药品监督管理局





- The top line
- FY 2025 Highlights
- Key market activities
- FY 2026 Strategy
- Revenue Outlook
- The TruScreen Team
- Appendix



NATIONAL MEDICAL PRODUCTS ADMINISTRATION
国家药品监督管理局



The top line





TruScreen Group Ltd is a revenue generating Life Science company with a unique, AI-enabled real-time cervical cancer screening device.

The Company manufactures two devices :

- one made in China for use in China, where locally manufactured products have preferential market access
- one in Australia for other markets

For each patient screened with the TruScreen device a new disposable Single Use Sensor (SUS) must be used. This creates a **recurring revenue model** with a consumable sale for each patient screened with TruScreen.



FY25 sales of NZ\$ 1.7m, compared to NZ\$ 2.1m in FY24.

This lower result was largely due to program delays in:

- Zimbabwe (program validation conducted Sept 2025)
- Vietnam (program launched April 2025, patient recruitment and clinician screening training commenced August 2025)
- Indonesia (registration achieved and first sale April 2025)
- Uzbekistan (registration achieved June 2025, and pilot program MOU signed August 2025)



TruScreen Group Ltd forecast FY26 sales to exceed NZ\$ 2.8m, making the Company monthly cash flow positive in March '26


FY26 revenue is forecast to be made up of revenue from our largest market China, plus additional channels for which the foundations were laid in FY25 – new distributors Indonesia and India, Public Screening Programs in Vietnam, Zimbabwe and Uzbekistan, and our new strategic alliance with Dalton Bio.

Combined with the agreement to distribute Dalton Bioscience HPV DNA equipment and kits this represents significant product and geographical diversification, broadening our business operations.


Financial results

	COVID impact			
NZD (m)	FY22 Actual	FY23 Actual	FY24 Actual	FY25 Actual
Sales	1.7	1.66	2.1	1.7
Total Revenue	2.7	2.2	2.6	2.1
COGS	1.3	1.3	1.4	1.2
R&D expenses	1.5	0.9	0.9	0.8
EBITDA	(2.7)	(2.4)	(2.0)	(2.2)
Loss for Year	(7.9)	(2.9)	(2.0)	(2.2)
Net assets	3.4	2.5	3.2	1.0
Cash	2.8	2.2	2.7	0.4

The FY 25 lower sales result was largely due to delays in roll-out programs in Vietnam (launched April 2025), and Zimbabwe (validation conducted September ‘25) and delayed product registrations in Indonesia and Uzbekistan. Revenues from these delayed commercial activities are expected to be realised in FY2026.



**Women
Screened**



**Devices operational
worldwide**




**Healthcare professionals
trained**



**WHO and UNITAID
recognition**




**Hospitals / Clinics
using TruScreen**



**Countries with
regulatory approval**




**Regulatory
approvals in process**



**Clinical Performance
validations**

Global Recognition



TruScreen Regulatory Approvals

Recognized by

- World Health Organisation (WHO)
- UNITAID
- Clinton Health Access Initiative
- Daffodil Foundation - Australia
- China Obstetricians and Gynaecologists Association
- China Society for Colposcopy and Cervical Pathology
- Russia Cervical Cancer Screening Guideline
- Vietnam Hospital Technical List

International Approvals:

- CE Mark, European Union
- NMPA, China
- TGA, Australia
- MHRA, UK
- SFDA, Saudi Arabia
- Roszdravnadzor, Russia
- COFEPRIS, Mexico
- WAND New Zealand
- Zimbabwe Ministry of Health
- IEAKI Indonesia
- Vietnam Technical List
- India (Test Licence)
- Uzbekistan

International Quality Accreditation:

- ISO 13485
- IEC 60601-1
- IEC 60601-1-2
- CE Mark

How The TruScreen Device works



1

A pen-like wand covered by a Single Use Sensor (SUS) is used to gently touch multiple spots on the cervix. The SUS contains a precision lens and electrodes which interfaces with the cervix. In doing so, it sends and picks up low level electrical and optical signals (14 readings per second) from the cervical tissue.

2

The TruScreen Handheld Device then applies as an integrated AI-enabled algorithm to analyse these signals and compares them to an integrated database of 2,000 patients drawn from a wide range of geographic and ethnic backgrounds with differing histological diagnoses. This analysis identifies the presence of abnormal (cancerous and pre-cancerous) cells in the cervix and provides physicians with real-time results.



Each TruScreen examination takes one to two minutes to produce results, compared to conventional Pap tests which can take days, weeks, or even months in some countries, for a result to be returned.

Commercial Strategy

THE INDIRECT CHANNEL


- Global distributors

THE DIRECT CHANNEL

- Major public screening programs supported by national Ministries of Health and Non-Government Organisations – Vietnam, Uzbekistan and Zimbabwe planned so far for FY26

PRODUCT PORTFOLIO EXPANSION

- Addition of market agreements to distribute Hangzhou Dalton Bioscience Limited's HPV DNA tests and equipment



FY 2025 Highlights



Capital raise oversubscribed - \$4m raised

\$2.3m

Placement

TruScreen raised \$2.3 million through a share Placement, with the issue of approximately 105 million shares at \$0.022 each.

\$1.67m

SPP


In addition, the Company has raised a further \$1.67 million with the issue of approximately 83.6 million shares through a Share Purchase Plan (SPP).

Options

Each Placement share and each SPP share has attached one share option with an exercise price of NZD \$0.022 and an expiry date one year from date of issue.


Funding allocation

- Growing TruScreen's presence in the Chinese market
- Distribution of Dalton Bio IVD HPV DNA products
- Executing public cervical cancer screening programs in Vietnam, Zimbabwe and Uzbekistan
- Development of African markets
- Continued development of the growing public cervical cancer screening sales channel with key NGOs and Ministries of Health
- Development of Indonesian and ASEAN markets
- Development of the Indian market
- Providing additional working capital



Entry into Public Screening Programs

- TruScreen's sales to date have been achieved largely through traditional sales of devices and Single Use Sensors to hospitals and clinics. In FY25 these traditional channels made up 99% of sales.
- In FY26, public screening programs are expected to contribute greater than 20% of total sales in FY26, with an increasing percentage of sales expected from these programs in future.




Vietnam

A 5-year program to screen 260,000 women for cervical cancer using TruScreen in Ho Chi Minh City launched in July 2025. The program is a partnership between TruScreen, Ho Chi Minh City Public Health Association and distributor Gorton Health Services, and will assist Vietnam to achieve its goal of screening 60% of women aged 30 to 54 for cervical cancer (currently 25%).



April 12 2025. TruScreen Chair Tony Ho, President of the Ho Chi Minh City Public Health Association Dr Le Truong Giang and Managing Director of Gorton Health Services Mr An Trang sign the formal agreement to conduct a 260,000 women screening program in Ho Chi Minh City.




Zimbabwe

Since 2022, TruScreen has screened 14,000 women in the Masvingo Province, Zimbabwe, through a public screening program managed by the Zimbabwe National AIDS Council (NAC) and the Ministry of Health and Childcare. Re-validation will be completed in September 2025 to recommence and expand the program to the Harare and other provinces - with 20,000 women expected to be screened in FY26.



TruScreen's Dr Carolina Velasquez training team in Zimbabwe, August 2025.



Uzbekistan

Following TruScreen's receipt of regulatory approval by the National Pharmaceutical Safety Committee in Uzbekistan in June 2025, a 500 patient pilot project is planned to commence in September/October in Karakalpakstan, Uzbekistan. Uzbekistan has over 11 million women of screening age*, and is also a major healthcare reference site for neighbouring Central Asian nations.



TruScreen CEO Marty Dillon signs MOU with Senator & Professor Aral Ataniyazova in Tashkent, Uzbekistan



The 'Pilot Project for the use of TruScreen' in Uzbekistan project team – Marty Dillon, Dr Klara Yadgarova, Senator & Professor Aral Ataniyazova and Professor Asimidin Kamilov

Medical Affairs achievements

OCT 24

- Included in UNITAID's technology landscape report "Screening and treatment of pre-cancerous lesions for secondary prevention of cervical cancer", the only opto-electrical device included.
- Selected by StartUs Insights as one of six global companies that will have an impact on global women's health.
- Invited to present at the WHO key meeting to further the use of AI technologies for screening of cervical cancer

NOV 24

Fudan University study¹ (n=1908), published by Springer Nature, concluded that TruScreen optoelectronic real time screening detection accuracy outperformed liquid-based cytology (LBC) in patients with type 3 cervical transformation zone.

APR 25

Saudi Arabia study² (n=507) investigating TruScreen's performance versus pap smears in cervical cancer detection published and peer reviewed by BMC Women's Health. Results showed that TruScreen demonstrated:

- High Sensitivity: TruScreen 83.3%, compared to Pap test 66.7%
- High Specificity: TruScreen 95%, compared to Pap test 98.2%

JUN 25

Beijing study³ (n=100) from 2018 was published by Dovepress, demonstrating higher sensitivity (86.4%) and higher specificity (74.4%) for screening cervical precancerous lesions in middle-aged women, compared to TCT and HR-HPV tests. The study also demonstrated increased efficacy when used in combination with TCT and HPV tests and validates TruScreen's emerging markets growth strategy and recent agreement to distribute DaltonBio's HPV IVD test products to India.

DaltonBio Strategic Alliance



- **Q4 FY25 - Memorandum of Understanding signed with Hangzhou Dalton Bioscience (DaltonBio)**
- **Q1 FY26 - TruScreen and Dalton Bio sign Distribution Agreement for HPV products in India**

Key points:

1. TruScreen to be appointed a global distributor of DaltonBio HPV related IVD products (excluding U.S.A. and Canada).
2. DaltonBio to explore opportunities to assist sales of TruScreen's AI enabled real time cervical screening device within its distribution network, notably in its selected distributors in China and South America. DaltonBio have 200 sub distributors in China which may augment TruScreen's current distribution network in it's largest market.

The collaboration will enhance access to innovative cervical cancer screening and detection solutions by leveraging the technology strengths of both companies. As demonstrated in the COGA landmark study (2023) and Beijing Obstetrics and Gynecology Hospital study (Dovepress, May 2025), co-testing improved TruScreen's already impressive standalone sensitivity significantly.

HPV tests-DH™ series by DaltonBio

Human Papillomavirus (HPV) Nucleic Acid Detection Systems HPV Self Sampling Collection System

The DH3 kit is used to detect 14 high-risk HPV types that cause cervical cancer, provides relative viral load values, and it has clinical guiding significance for screening high-risk groups of cervical precancerous lesions.

DH3 can distinguish HPV-16/18 and achieve risk stratification management. The hybrid capture technology it applies does not require nucleic acid extraction and amplification, and has exceptional reproducibility and negative predictive value. The use of HPV full-length probes can effectively avoid missed diagnosis.



**14 High-risk
HPV types**



**18 High- & medium-risk
HPV types**



Key market activities






Key market China accounted for over 85% of global sales and exceeded budget in FY25 and is now poised for expansion in 6 key provinces

- **Key provinces for growth:** TruScreen's China distributor Beijing Siweixiangtai Technology Co Ltd (SWXT) is targeting 6 key provinces for growth in FY26 - Guangxi, Jiangsu, Hunan, Zhejiang, Shanghai and Guangdong. These provinces have a combined population of 496 million, and an addressable screening market of approximately 124 million women.
- **TruScreen unaffected by US and China proposed tariff regimes:** TruScreen markets both an Australian and a Made in China device, providing a dual product strategy in the key China market, with preferential market access for China manufactured products
- **30% increase in SUS Pull Through:** Consumable Single Use Sensor (SUS) pull through per month per device has reached peak of 142 SUS per month per device, an increase of 30 % over 12 months.
- **Software Upgrade:** China's NMPA registration variations have been approved and software upgrade on Chinese devices has commenced. The upgrade will improve user experience for clinicians and extend the device's in-use service interval.



- **Private Sector Expansion:** SWXT targeting of the growing China private health sector including private clinic and Health Check Centre approvals in Jiangsu and Shenzhen, and entry into the Luxury Hospital and Traditional Chinese Medicine Hospital sectors.
- **Public Health Insurance:** In addition to having 11 provinces with approved pricing for TruScreen, Beijing has awarded public health insurance reimbursement for eligible TruScreen patients. Shanghai has completed the final round of evaluation for public health insurance reimbursement and once the administrative processes for this are formalised sales are expected to grow rapidly in this province.



In April 2025 TruScreen and SWXT planned the expansion of TruScreen sales in China. From left to right: Mr Li, partner SWXT, Marty Dillon, CEO TruScreen, Miss Su Siming, Managing Director SWXT, Tony Ho, Chair TruScreen and Mr Wang, SWXT manager of TruScreen business in China



TruScreen selected to screen 260,000 women in Ho Chi Minh City and adoption in Vietnam picks up pace – expected to be second largest market in FY2026

5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City launched July 2025

Following the signing of a Memorandum of Understanding with the Ho Chi Minh City Public Health Association and Gorton Health Services (Truscreen's Vietnam distributor) in November, TruScreen has been selected as the primary screening methodology for the capability of its unique, AI-enabled real time cervical cancer screening technology to assist the Government of Vietnam achieve its goal of screening 60% of women aged 30 to 54 for cervical cancer (currently only 25% screened).

VIETNAM

**36 million
women of
screening age***

Public Hospital Adoption

In January 2025 Professor Michael Campion presented at Tu Duc Hospital in Ho Chi Minh City, leading to 6 major Ho Chi Minh City hospitals agreeing to adopt and install TruScreen.



April 12 2025. TruScreen Chair Tony Ho, President of the Ho Chi Minh City Public Health Association Dr Le Truong Giang and Managing Director of Gorton Health Services Mr An Trang sign the formal agreement to conduct a 260,000 women screening program in Ho Chi Minh City.



TruScreen re-enters India with appointment of Renovate Biologicals Pvt Ltd in April 2025

India holds one-sixth of the world's population and one woman dies from cervical cancer every eight minutes in the country. The cervical cancer screening rate is only 2%, and India's National Academy of Medical Sciences (NAMS) has recently set a target of 70% by 2030.

First sales have been completed, and TruScreen has already been used in 1800 women program in Ladakh, NW India. The appointment of Renovate Biologicals now gives TruScreen distribution capability in 3 of the 4 most populous countries in the world - China, India and Indonesia. In addition to the distribution of TruScreen devices and SUS's, TruScreen will also commence distribution of Dalton Bio's HPV IVD products in India – the first market agreement to be made as part of the Dalton Bio strategic alliance.

INDIA

**468 million
women of
screening age***



Marty Dillon with the Renovate Biologicals team in Hyderabad, India, August 2025.



Indonesia product registration completed and distributor appointed, with commercial activity commenced in May 2025

- **Distributor Appointed:** Following the completion of product registration, TruScreen appointed a new Indonesian medical products distributor PT Mawar Mitra Medika with commercial sales commenced in the world's largest Islamic nation, with a population spread over 14,000 islands. TruScreen offers an ideal solution to providing screening to a geographically dispersed and diverse population.
- **AI presentation by CEO to MOH officials and KOL's.** In December 2024, TruScreen presented to an AI Health webinar organised by Austrade and the Indonesian Ministry of Health. TruScreen was one of only two companies invited to present at this webinar, a recognition of our growing reputation as a leader in AI innovative health technology with a particular relevance to emerging economies.

INDONESIA

96 million
women of
screening age*




Mexico second largest market in FY2025, accounting for 7% of sales – with major private health insurer opportunity in play

Mexico has approximately 46 million women of screening age*, and cervical cancer is the second most prevalent cancer amongst women.

HPVcentre.net estimates that 9,400 women are diagnosed annually with cervical cancer with a very high mortality rate of 46% - 4,300 deaths.

Mexico's national regulator, COFEPRIS, approved TruScreen for use in the public health sector in FY2024, allowing TruScreen's distributor Sunbird S.A de C.V. to target the wider public health sector (70.9% of the population access the public health system).

Mexico represented TruScreen's second largest market after China in FY2025, with new device installations continuing. TruScreen is currently awaiting the outcome of a tender for the Instituto Mexicano del Seguro Social (IMSS) the largest social security and health institution in Mexico for the use of an opto electrical medical device for a cervical cancer screening program.



African opportunities progress, with Zimbabwe PSP expected to launch Q3 FY2026



Zimbabwe

Since 2022, TruScreen has screened 14,000 women in the Masvingo Province, Zimbabwe, through a public screening program managed by the Zimbabwe National AIDS Council (NAC) and the Ministry of Health and Childcare. Formal re-validation is being undertaken by the Ministry of Health, in order to expand the program. The clinical component of this re-validation has been completed and the analysis of results is to be completed in September 2025.

With limited pathology services and no nationwide recall system for follow-up appointments, traditional screening methods such as cytology are not suitable for Zimbabwe's population. TruScreen, which enable a 'see and treat' screening service, is ideally suited to fill the gap in Zimbabwe's women healthcare system.

ZIMBABWE

5 million
women of
screening age*



Eswatini

In May 2025, TruScreen and the Baylor Foundation Eswatini agree on the validation and initial product training for TruScreen to be used for a pilot program to screen women in Eswatini (formally Swaziland). Co-funding is being sought to replace the cancelled USAID funding component.

ESWATINI

390,000
women of
screening age*

FY 2026 Strategy



Key Objectives for FY2026

PSP success

- Successful execution of PSPs in Vietnam, Zimbabwe and Uzbekistan
- Create an operating process for success
- Continue development of the growing public cervical cancer screening sales channel with key NGOs and Ministries of Health

Dalton sales

- Build on initial India sales
- Sign new market agreements

Development of ASEAN market

- Build Indonesia sales with PT Mawar Mitra Medika
- Work with Intega to deliver sales in Singapore, Malaysia and Thailand

Development of Indian market

- Build sales with Renovate (TRU and Dalton)



Monthly cash flow positive in Mar 26

Key Enablers of Success

New BDM hire

HIRED AUGUST 2025

- Dalton relationship nurture, including exploring opportunities to grow TruScreen's presence in the Chinese market through Dalton distribution network
- Public screening program management
- MOH's/NGO's and Foundations marketing

Strengthen distributor relationships

- Refine partner support processes to deliver maximum value – improve marketing collateral and sharing of information via Quarterly distributor meetings
- Refine pricing strategy to suit market needs – experiment with differential pricing via selected support programs

Build evidence base and international recognition

- Get COGA paper published and review interim data from Uzbekistan and HPHA
- Build on International NGO Recognition (WHO, UNITAID, CHAI, COGA, CSCCP) to build acceptance and remove barriers to sale


Marcomms focus

- Website quality uplift and brand refinement
- Social promotion of all activities and successes in order to build existing investor confidence and attract new investors
- Collect marketing case studies

Continued operational cost-effectiveness

- Keep head count low
- Streamline internal processes to create more efficiencies in the day to day - enable CEO to focus on Sales more than admin
- Continue to seek SUS cost improvements.
- Manufacturing and QA/Reg software to lower consultant costs.
- Investigate potential AI contribution to efficiency

FY2026 active markets - at a glance (note: PSP = Public Screening Program)



Growth Strategies



Market expansion to continue with China the key focus



Focus on key growth provinces (Shandong, Jiangsu,, Hunan, Zhejiang, Guangdong, Guangxi) - Total popn 496m



Strengthen China Distribution Capability via Strategic Partnership with Dalton Bio



Strengthen vertical Asian market from Indonesia through China, and capitalise on Indian distribution network



Target Govt and NGO funded programs in addition to Zimbabwe, Vietnam, Mexico and Uzbekistan



Build on International NGO Recognition (WHO, UNITAID, CHAI, COGA , CSCCP) to build acceptance and remove barriers to sale

Growth Strategies (cont.)



Focus on countries with limited or nil cervical screening capability



Developing strategic partnerships for complementary woman's health services



Capitalise on global focus on AI enabled cervical cancer technologies – e.g. WHO



Expand product portfolio to include Dalton Bio HPV related IVD products DNA tests, including HPV DNA tests and self sampling



Reduce SUS and Device COGS and increase profitability

Revenue Outlook





FY25 Sales (Actual)

NZ\$ 1.71m

FY26 Sales (Projection)

NZ\$ 2.8m

+64% YOY increase with increased diversification of revenue



TruScreen Expected Sales Increase FY26





China

>NZ\$1.75m

- FY26 expectations are a 13% uptick on FY25 sales
- Distributor SWXT have forecast sales of 40 Devices and 150,000 SUS for FY 26
- Expected to represent ~60% of Global Sales – a ~30% reduction in our reliance on China sales (87% in FY25), mitigating a key business risk



Vietnam

>NZ\$150k

FY26 sales expectations underpinned by two key factors:

- Ho Chi Minh City Public Screening Program commenced August 2025
- Agreements from 6 major Ho Chi Minh City hospitals following the inclusion in the Vietnam National technical list and Prof Campion's presentation at Tu Duc Hospital in Jan 2025



India

>NZ\$150k

FY26 forecast is based upon the contracted Yr 1 of sales to new distributor Renovate Biologicals, for which the first order has already been placed (August 2025)



Indonesia

>NZ\$100k

FY26 forecast is based upon the contracted Year 1 of sales to new distributor PT Mawar Mitra Medika, with first order already placed.



Uzbekistan

>NZ\$100k

FY26 sales expectations underpinned by the commencement of 500-patient pilot program in Karakalpakstan, Uzbekistan and potential for expansion province by province.



Mexico

>NZ\$100k

FY26 Forecast is based upon modest growth from FY25, building upon the inclusion in the Mexico COFEPRIS approval for use in the public health system in Mexico. Distributor Sunbird continues to engage with the newly elected government officials to introduce TruScreen to the public health sector, and are in advanced discussions with IMSS (the nation's largest public health insurer covering 38% of the population) for TruScreen inclusion in their planned cervical cancer screening program



Zimbabwe

>NZ\$250k

FY26 forecast is based upon the recommencement of public screening programs in metropolitan and regional Zimbabwe, once Ministry of Health Re-Validation has been finalised in September 2025.



Singapore, Malaysia and Thailand

TruScreen is working with distributor INTEGA to introduce TruScreen into this region. Documents have been supplied to commence the registration of TruScreen in these countries and a key opinion leader, Dr Quek Swee Cheong has agreed to use TruScreen both in his private clinic and programs conducted by him in India and Nepal.

Dalton Bio


>NZ\$200k

FY26 sales expectations expected to account for ~7% of sales in FY26. The first formal distribution agreement was signed in May 2025, for TruScreen to distribute DaltonBio's HPV detection products in India, and the first order has already been placed.

The TruScreen Team



The Board



Mr. Anthony Ho
B. Com (UNSW), CA, FAICD, FCIS, FGIA

Non-executive Chairman

A Director and Chairman of a number of listed ASX companies.

Previous Executive Director of sales and distribution company Arthur Yates & Co Limited, as well as Finance Director and CFO of listed ASX retailers M. S. McLeod Holdings Limited (Downtown Duty Free), Galore Group Limited (Barbeques Galore) and Brazin Limited (Bras N Things, Sanity Music).



Mr. Christopher Horn
B. Com (UNSW), FCA

Non-executive Independent Director

An experienced business executive and has acted in a number of management roles including 20 years as a senior partner of KPMG and its predecessor firms. Director of a number of private companies across a broad range of business activities including corporate advisory, financial services, and funds management. UNSW Commerce graduate and Fellow of Chartered Accountants Australia and New Zealand



Dr. Dexter Cheung
B. Tech (Hons), M.Eng, PHD

Non-executive Director

Experienced medical device engineer and specialist in product R+D. Research and Development Manager of the respiratory humidification division of ASX/NZX-listed Fisher & Paykel Healthcare. Brings 20 years' experience in manufacturing, working with suppliers across the globe. His technical background in opto-electronics and expertise in medical device engineering is highly relevant to TruScreen, who's cervical cancer screening device harnesses opto-electronic signatures for screening results.



Ms. Juliet Hull
B.Nurse ATI, MBA MGSM

Non-executive Director

MBA from the Macquarie Graduate School of Management, and Bachelor of Nursing from the Auckland Technical Institute. More than 20 years' experience working in Asia and Pacific markets in Healthcare, in sales, Marketing and leadership. Juliet was the General Manager/Country Director for Johnson & Johnson Medical in New Zealand and has held various roles in Johnson & Johnson in Australia and New Zealand since 2012.

The Executive Team



Martin Dillon

CEO

Martin Dillon skilfully managed the company's listing on the NZX and oversees its strategic vision. With over 30 years of commercial experience, he has engaged with health and regulatory authorities worldwide and held numerous senior executive roles in private and public companies in healthcare, advertising and marketing.



Guy Robertson, B. Com (Hons.) CA

CFO & Company Secretary

Guy is an experienced finance executive, having held the positions of Director, Company Secretary and Chief Financial Officer of both private and ASX-listed companies in Australia and Hong Kong. Guy held senior roles in the Jardine Matheson Group of Companies, including General Manager Finance of Franklins Limited, Chief Operating Officer of Colliers International Asia Pacific and Managing Director (NSW) Jardine Lloyd Thompson.



Dr Jerry Tan
B. Med (Clinical), M.Com, CPA

General Manager Commercial

Dr. Tan has extensive knowledge of the TruScreen product and has been involved in establishing key markets in China, Vietnam, Mexico and Indonesia. Dr Tan is a qualified gynaecologist and has been working with opto-electric screening technology for over two decades and has led the commercialisation of TruScreen since the company's establishment in 2013. He oversees global commercial operations.

The Executive Team



Dr Carolina Velasquez
MBBS, M ClinRes

Medical Affairs and Training Manager

Dr Carolina Velasquez gained her Bachelor of Medicine and Surgery at Pontificia Universidad in Colombia and her Masters in Clinical Research at Monash University in Melbourne . She has 8 years experience with Truscreen conducting operator training and supervising clinical trials in Australia, India, Zimbabwe, China, Vietnam, Indonesia and Mexico. Dr Velasquez also co-ordinates the work of both Truscreen's Medical Advisory Committee and international Medical Experts Group.



Usharani Raji
B Eng (Hons), MSc

Production Manager

Usha is an experienced engineer with a strong background in process development and manufacturing, across medical devices, printhead and semiconductor technologies. With a strong focus on continuous improvement and lean manufacturing, she has successfully transitioned prototypes to scalable production and trained international teams. She is passionate in delivering high quality product, through engineering excellence. Usha oversees TruScreen device production, supporting R&D projects and lead Service & Repair and field issues globally

Contact us




Martin Dillon
CEO

M - +61 449 115 065
E – martindillon@truscreen.com

TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia

www.truscreen.com



Guy Robertson
Chief Financial Officer

M – +61 407 983 270
E – guyrobertson@truscreen.com

TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia

www.truscreen.com

References

*Women aged 15-64 years as detailed in the World Fact Book : <https://www.cia.gov/the-world-factbook/>

¹ Xiao, F., Sui, L. Evaluation of a real-time optoelectronic method for the detection of cervical intraepithelial neoplasia and cervical cancer in patients with different transformation zone types. *Sci Rep* 14, 27220 (2024). <https://doi.org/10.1038/s41598-024-78773-w>

² Alhudhud, M., Maqsood, S., Hussein, M.E. *et al.* Cervical cancer screening: a comparative study of TruScreen vs. Pap Smear. *BMC Women's Health* **25**, 198 (2025). <https://doi.org/10.1186/s12905-025-03733-z>

³ Gao S, Tian Y, Song F, Wang J. Assessment of the Real-Time Photoelectric Detection Device (TruScreen) in Screening for Cervical Precancerous Lesions in Middle-Aged Women: An Observational Study. *Risk Manag Healthc Policy*. 2025;18:1783-1791 <https://doi.org/10.2147/RMHP.S524022>

Disclaimers

This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The information in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company. This presentation should be read in conjunction with the Company’s annual report, market releases and other periodic and continuous disclosure announcements, which are available at www.nzx.com. This presentation does not constitute an offer, advertisement or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer, advertisement or invitation.

Not financial product advice

This presentation is for information purposes only and is not financial or investment advice or a recommendation to acquire the Company’s securities, and has been prepared without taking into account the objectives, financial situation or needs of prospective investors. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and consult a financial adviser, solicitor, accountant or other professional adviser if necessary.

Past performance

Any past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. No representations or warranties are made as to the accuracy or completeness of such information.


Future performance

This presentation includes certain “forward-looking statements” about the Company and the environment in which the Company operates. Forward-looking information is inherently uncertain and subject to contingencies, known and unknown risks and uncertainties and other factors, many of which are outside of the Company’s control, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. A number of important factors could cause actual results or performance to differ materially from any forward-looking statements. No assurance can be given that actual outcomes or performance will not materially differ from the forward-looking statements. The forward-looking statements are based on information available to the Company as at the date of this presentation. Except as required by law or regulation (including the Listing Rules), the Company undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Appendix:



The TruScreen Journey



- Enabled by AI, TruScreen provides an **accurate, real time** cervical cancer screening solution
- Each TruScreen examination takes **one to two minutes to produce results**, compared to conventional Pap tests which can take days, weeks, or even months in some countries, for a result to be returned.



How it works

1

a pen-like wand covered by a **Single Use Sensor (SUS)** is used to gently touch multiple spots on the cervix. The SUS contains a precision lens and electrodes which interfaces with the cervix. It sends and picks up low level **electrical and optical signals** (14 readings per second) from the cervical tissue.



How it works

2

The TruScreen **Handheld Device (HHD)** then applies an integrated AI-enabled algorithm to analyse these signals and compares them to an integrated database of 2,000 patients drawn from a wide range of geographic and ethnic backgrounds with differing histological diagnoses.

This identifies the presence of abnormal (cancerous and pre-cancerous) cells in the cervix and provides physicians with real-time results.



- ✓ Clinicians/physicians are able to **immediately plan appropriate patient care**
- ✓ Device has an expected life span of 5–7 years
- ✓ **Disposable SUS is used once per test per patient - ensures** there is no chance of cross-infection between patients
- ✓ The entire patient data collection and analysis is self-checked and controlled. **No tissue sample needs to be taken.** These measures ensure that the results are reliable and consistent, and that the examination is painless and safe
- ✓ **TruScreen has been used on over 1 million women and there has never been a single adverse event reported**



COGA Trial (n= 15,661, 2018-2021)

- TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV
- TruScreen determined to be a simple, effective and rapid real-time cervical cancer screening method
- TruScreen determined to be an appropriate primary cervical cancer screening tool in regions with high morbidity and mortality to cervical cancer
- Also highlighted the superiority of TruScreen against alternative screening methods as well as the potential benefits of a TruScreen-HPV co-testing. The size of the COGA study, which was TruScreen's largest clinical evaluation to date, lends extra significance to its results and broad conclusions.

**TruScreen's
sensitivity**
was well above that for LBC
(87.5% v's 66.5%), with a high
degree of statistical
significance ($p < 0.001$).

**The sensitivity of TruScreen-hrHPV co-
testing (carrying out with multiple types
of screening tests at the same time, as
opposed to a single type) was higher than
that of LBC-hrHPV co-testing,
98.4% vs 95.9%
(statistically significant at $p = 0.006$).**

**TruScreen's
specificity**
(88.4%) was higher than both
LBC (86.3%) and hrHPV
testing (78.3%) (also at
 $p < 0.001$).

*These results were presented at a research conference organised by ASCCP (American Society of Colposcopy and Cervical Pathology) in San Diego, USA in 2021.
The COGA trial manuscript is currently being reviewed for publishing in the Journal of the American Medical Association (JAMA).*

Why TruScreen?

	Truscreen	Liquid Based Cytology (LBC)	HPV DNA
Real time results	✓		
Low infrastructure costs	✓		
Strong clinical results	✓	✓	✓
Objective results	✓		
Low training threshold	✓		
Portable	✓		
No cell or tissue samples taken	✓		